Anergis raises $19.6 million in series A

Allergy company Anergis S.A. (Epalinges, Switzerland) raised CHF18 million ($19.6 million) in a series A round co-led by Vinci Capital - Renaissance PME; BioMedInvest; and Sunstone. Esperante BV; Initiative Capital Romandie; and private investors also participated. Anergis' lead product is AllerT, which consists of peptides derived from major birch pollen allergen Bet v 1. Anergis plans to begin Phase IIb testing of the product this fall to desensitize patients allergic to birch pollen. ...